PRVB Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

$6.29  -0.16 (-2.48%)
As of 12/06/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/24/2018
Outstanding shares:  63,374,738
Average volume:  915,033
Market cap:   $408,767,060
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74374N102
ISIN:        US74374N1028
Sedol:      BG346B3
Valuation   (See tab for details)
PE ratio:   -15.13
PB ratio:   3.05
PS ratio:   0.00
Return on equity:   -90.36%
Net income %:   -17,873,156.34%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy